Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3445
Source ID: NCT05046873
Associated Drug: Co-Formulation Nnc0480 0389+Semaglutide A 10/1 Mg/Ml
Title: A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL|DRUG: semaglutide 1.34 mg/mL (placebo)|DRUG: Semaglutide 1.34 mg/mL|DRUG: NNC0480-0389 A 10 mg/mL
Outcome Measures: Primary: AUC0-∞,sema,SD: Area under the semaglutide plasma concentration-time curve after a single dose, h\*nmol/L, From baseline (visit 2/12, day 1, pre-dose) until completion of the assessment period (visit 11/21, day 36)|AUC0-∞,NNC0480-0389,SD: Area under the NNC0480-0389 plasma concentration-time curve after a single dose, h\*nmol/L, From baseline (visit 2/12, day 1, pre-dose) until completion of the assessment period (visit 11/21, day 36) | Secondary: Cmax,sema,SD: Maximum plasma concentration of semaglutide after a single dose, nmol/L, From baseline (visit 2/12, day 1, pre-dose) until completion of the assessment period (visit 11/21, day 36)|Cmax,NNC0480-0389,SD: Maximum plasma concentration of NNC0480-0389 after a single dose, nmol/L, From baseline (visit 2/12, day 1, pre-dose) until completion of the assessment period (visit 11/21, day 36)
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT
Phases: PHASE1
Enrollment: 16
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2021-09-06
Completion Date: 2022-01-05
Results First Posted:
Last Update Posted: 2023-07-03
Locations: Novo Nordisk Investigational Site, Berlin, 14050, Germany
URL: https://clinicaltrials.gov/show/NCT05046873